Pay in 4 interest-free payments of $6.17 Learn more
Ships within 48 hours · Estimated delivery Aug 10 - Aug 15
As GLP-1 receptor agonists (GLP-1s) like semaglutide (Wegovy, Ozempic) and tirzepatide (Mounjaro, Zepbound) become increasingly common in the treatment of diabetes, obesity, and cardiovascular disease, retina specialists are paying close attention to whether the drug therapies may influence ocular disease in already high-risk patients
These include D51.0 (due to intrinsic factor deficiency), D51.1 (selective malabsorption with proteinuria), D51.2 (transcobalamin II deficiency), D51.3 (dietary deficiency), D51.8 (other specified B12 deficiency anemias), and D51.9 (unspecified)
Online sales channels are capturing a notable share of this growth, presenting ample opportunity for brands to capitalize on digital platforms
FAQ Resources We Trust Cleveland Clinic: The Gastroparesis Diet Mayo Clinic: Gastroesophageal Reflux Disease (GERD) National Institute of Diabetes and Digestive and Kidney Diseases: Treatment for Gastroparesis Johns Hopkins Medicine: Digestive Disorders American Diabetes Association: Tips for Eating Well How Does Gastroparesis Affect People With Diabetes
Cell 66 , 807815 (1991)
Pediatr Res 16 : 490493
